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Introduction 
  
INTRODUCTION 
DIABETES MELITUS  
Diabetes is a condition in which the body does not produce or respond to insulin, a 
hormone that regulates the level of sugar in the blood. Diabetes mellitus arises when 
insufficient insulin is produced or when the available insulin does not function correctly. 
Without insulin, the amount of glucose in the blood stream is abnormally high, causing 
unquenchable thirst and frequent urination. The body's inability to store or use glucose 
causes hunger and weight loss. 
HISTORY1 
Physicians have observed the effects of diabetes for thousands of years. For much of this 
time, little was known about this fatal disease that caused wasting away of the body, 
extreme thirst and frequent urination. It wasn't until 1922 that the first patient was 
successfully treated with insulin. 
One of the effects of diabetes is the presence of glucose in the urine (glucosuria). Ancient 
Hindu writings, many thousands of years old, document how black ants and flies were 
attracted to the urine of diabetics. The Indian physician Sushruta in 400 B.C. described 
the sweet taste of urine from affected individuals and for many centuries to come, the 
sweet taste of urine was key to diagnosis. 
Around 250 B.C., the name “diabetes” was first used. It is a Greek word that means “to 
Syphon”, reflecting how diabetes seemed to rapidly drain fluid from the affected 
individual. The Greek physician Aretaeus noted that as affected individuals wasted away, 
they passed increasing amounts of urine as if there was “liquefaction of flesh and bones 
into urine”. The complete term “diabetes mellitus” was coined in 1674 by Thomas Willis, 
personal physician to King Charles II. Mellitus is Latin for honey, which is how Willis 
described the urine of diabetics (“as if imbued with honey and sugar”). 
 
        
  
Up until the mid-1800s, the treatments offered for diabetes varied tremendously. Various 
“fad” diets were prescribed and the use of opium was suggested, as were bleeding and 
other therapies. The most successful treatments were starvation diets in which calorie 
intake was severally restricted. Naturally, this was intolerable for the patient and at best 
extended life expectancy for a few years. 
A breakthrough in the puzzle of diabetes came in 1889. German physicians Joseph von 
Mering and Oskar Minkowski surgically removed the pancreas from dogs. The dogs 
immediately developed diabetes. Now that a link was established between the pancreas 
gland and diabetes, research focused on isolating the pancreatic extract that could treat 
diabetes. 
To concentrate what we now know as insulin, Banting tied the pancreatic ducts of dogs. 
The pancreatic cells that released digestive enzymes (and could also destroy insulin) 
degenerated, but the cells that secreted insulin were spared. Over several weeks the 
pancreas degenerated into a residue from which insulin could be extracted. In July 1921, 
a dog that had its pancreas surgically removed was injected with an extract collected from 
a duct-tied dog. In the two hours that followed the injection, the blood sugar level of the 
dog fell and its condition improved. Another de-pancreatized (diabetic-like) dog was kept 
alive for eight days by regular injections until supplies of the extract, at that time called 
"isletin", were exhausted. 
Further experiments on dogs showed that extracts from the pancreas caused a drop in 
blood sugar, caused glucose in the urine to disappear, and produced a marked 
improvement in clinical condition. So long as the extract was being given, the dogs were 
kept alive. The supply of the extract was improved: the pancreases of different animals 
were used until that of the cow was settled upon. This extract kept a de-pancreatized dog 
alive for 70 days. Dr. J. Collip, a biochemist, was drafted to continue improving the 
purity of the pancreas extract, and later, best carried on this work.  
 
 
  
A young boy, Leonard Thompson, was the first patient to receive insulin treatment. On 
January 11, 1922, aged 14 and weighing only 64 pounds, he was extremely ill. The first 
injections of insulin only produced a slight lowering of blood sugar level. The extract still 
was not pure enough, and abscesses developed at the injection site. Collip continued to 
refine the extract. Several weeks later, Leonard was treated again and showed a 
remarkable recovery. His blood sugar levels fell; he gained weight and lived for another 
13 years. He died from pneumonia at the age of 27. 
During the spring of 1922, best increased the production of insulin to enable the 
treatment of diabetic patients coming to the Toronto clinic. Over the next 60 years, 
insulin was further refined and purified, and long-acting and intermediate types were 
developed to provide more flexibility. A revolution came with the production of 
recombinant human DNA insulin in 1978. Instead of collecting insulin from animals, new 
human insulin could be synthesized. 
 In 1923, Banting and Macloed were awarded the Nobel Prize for the discovery of 
insulin. Banting split his prize with Best and Macloed split his prize with Collip. In his 
Nobel Lecture, Banting concluded the following about their discovery. 
“Insulin is not a cure for diabetes; it is a treatment. It enables the diabetic to burn 
sufficient carbohydrates, so that proteins and fats may be added to the diet in sufficient 
quantities to provide energy for the economic burdens of life.” 
STATISTICAL DATA     
The most common forms of diabetes are type 1 diabetes (5%) 2, which is an autoimmune 
disorder and type 2 diabetes (95%) 3, which is associated with obesity.  Over 18 million 
Americans have diabetes; of these, about 5 million do not know they have the disease. 
When people think of epidemics, they often think of infectious diseases such as SARS, 
HIV or the flu. However, the prevalence of type 2 diabetes is now at epidemic 
proportions. In the United States, diabetes accounts for over 130 billion dollars of health 
care costs and is the fifth leading cause of death. The number of new cases being 
diagnosed continues to rise. It has been estimated that of the children born in the year 
  
2000, 1 of 3 will suffer from diabetes at some point in their lifetime. Diabetes is predicted 
to become one of the most common diseases in the world within a couple of decades, 
affecting at least half a billion people. 
In the past, type 2 was rarely seen in the young, hence its original name of “adult-onset 
diabetes”. But now type 2 diabetes is increasingly being diagnosed in young adults and 
even in children. In Japan, more children suffer from type 2 than type 1 (“juvenile onset”) 
diabetes. This young generation of diabetics will have many decades in which to develop 
the complications of diabetes. In 1990, 4.9% of the American populations were 
diagnosed with diabetes. This increased to 7.9% by the year 20014. 
Type 2 diabetes comprises 90% of people with diabetes around the world and is one of 
the major public health challenges of the 21st century. The number of cases worldwide in 
2000 is estimated to be about 171 million and is projected to rise to 366 million in 2030. 
The World Health Organization (WHO) projects that without urgent action, diabetes-
related deaths will increase by more than 50% in the next 10 years. Especially in upper-
middle income countries, diabetes deaths are projected to increase by over 80% between 
2006 and 2015. 
TYPES 
The three main types of diabetes are: 
Type 1 diabetes  
Type 2 diabetes  
Gestational diabetes.  
 
 
 
  
Type 1 diabetes 
 Type 1 diabetes (once known as insulin-dependent diabetes mellitus or juvenile diabetes) 
is considered an autoimmune disease. An autoimmune disease results when the body's 
system for fighting infection (the immune system) turns against a part of the body. In 
diabetes, the immune system attacks the insulin-producing beta cells in the pancreas and 
destroys them. The pancreas then produces little or no insulin.  
Type 1 diabetes develops most often in children and young adults, but the disorder can 
appear at any age. Symptoms of type 1 diabetes usually develop over a short period, 
although beta cell destruction can begin years earlier.  
Type 2 diabetes 
The most common form of diabetes is type 2 diabetes (once known as noninsulin-
dependent diabetes mellitus or NIDDM). About 90 to 95 percent of people with diabetes 
have type 2 diabetes. This form of diabetes usually develops in adults over the age of 40 
and is most common among adults over age 55. About 80 percent of people with type 2 
diabetes are overweight.  
In type 2 diabetes, the pancreas usually produces insulin, but for some reason, the body 
cannot use the insulin effectively. The end result is the same as for type 1 diabetes--an 
unhealthy buildup of glucose in the blood and an inability of the body to make efficient 
use of its main source of fuel.  
Gestational Diabetes 
Gestational diabetes develops or is discovered during pregnancy. This type usually 
disappears when the pregnancy is over, but women who have had gestational diabetes 
have a greater risk of developing type 2 diabetes later in their lives.  
 
 
  
SYMPYTOMS 
Symptoms of Type I diabetes may include:  
 increased thirst and urination  
 constant hunger 
 weight loss 
 blurred vision  
 Extreme tiredness.  
Symptoms of Type 2 diabetes may include:  
 feeling tired or ill  
 frequent urination (especially at night)  
 unusual thirst  
 weight loss  
 blurred vision  
 frequent infections  
 Slow healing of sores.  
 having dry, itchy skin, tingling in the feet  
CAUSES 
In type 1 diabetes, the insulin-producing beta cells are destroyed by an autoimmune 
process, whereby the body's immune system - its defense mechanism against disease for 
some reason recognizes the cells as being 'foreign' rather than 'self' and therefore attacks 
them.  
Type 2 diabetes is thought to be due both to defects in the islet beta cells, so that less 
glucose is produced and to an impairment of insulin's ability to stimulate the uptake of 
glucose in muscles and other tissues. There is a genetic influence, as type 2 diabetes tends 
to run in families even more strongly than type 1 diabetes and several genes are likely to 
be involved. But increasing age, obesity and a sedentary lifestyle also increase the risk of 
type 2 diabetes.  
  
PATHOPHYSIOLOGY 
 
 
 
 
 
 
 
 
 
  
COMPLICATIONS  
Keep Diabetics Healthy
Diabetic
Retinopathy
Leading cause
of blindness
in adults
Diabetic
Nephropathy
Leading cause of 
end-stage renal disease
Cardiovascular
Disease
Stroke
2- to 4-fold increase in 
cardiovascular 
mortality and stroke
Diabetic
Neuropathy
Leading cause of
non-traumatic lower 
extremity amputations
8/10 individuals with 
diabetes die from CV 
events
 
 
TREATMENT 
The goal of diabetes management is to keep blood glucose levels as close to normal as 
safely possible. Since diabetes may greatly increase risk for heart disease and peripheral 
artery disease, measures to control blood pressure and cholesterol levels are an essential 
part of diabetes treatment as well. 
Dietary Management and Physical Activity 
Modifying eating habits and increasing physical activity are typically the first steps 
toward reducing blood sugar levels. At UCSF Medical Center, all patients work with 
their doctor and certified dietician to develop a dietary plan. Our Teaching Center 
conducts workshops that provide patients with information on food nutrient content, 
healthy cooking and exercise. 
 
  
Insulin Therapy 
People with type 1 diabetes require multiple insulin injections each day to maintain safe 
insulin levels. Insulin is often required to treat type2 diabetes too. Using an insulin pump 
is an alternative to injections. The pump is about the size of a pager and is usually worn 
on your belt. Insulin is delivered through a small tube (catheter) that is placed under the 
skin (usually in the abdomen). 
There are four major types of insulin: 
 Rapid-acting 
 Short-acting 
 Intermediate-acting 
 Long-acting 
Your doctor will determine your dose and how often you need to take insulin. There is no 
standard insulin dose as it depends on factors such as your body weight, when you eat, 
how often you exercise and how much insulin your body produces. 
Oral Medications 
Sometimes blood sugar levels remain high in people with type 2 diabetes even though 
they eat in a healthy manner and exercise. When this happens, medications taken in pill 
form may be prescribed. The medications work in several different ways. These include 
improve the effectiveness of the body's natural insulin, reduce blood sugar production, 
increase insulin production and inhibit blood sugar absorption. Oral diabetes medications 
are sometimes taken in combination with insulin. 
 
 
 
 
 
  
Aldose Reductase Inhibitor5 
Aldose reductase (AR) inhibitor is a class of drugs being studied as a way to prevent eye 
and nerve damage in people with diabetes.          
 
During Hyperglycemia, glucose entering the polyol pathway is reduced to sorbitol by 
Aldose reductase (AR) and NADPH. Sorbitol is subsequently oxidized to fructose by 
sorbitol dehydrogenase and NAD+. This increased flux through the polyol pathway 
results in a change in redox potential for these cofactors. The increased ratio of cytosolic 
NADH to NAD+ is called reductive stress, which has been linked to depleted 
intracellular levels of glutathione, increased nonenzymatic glycation and activation of 
protein kinase C. In addition to reductive stress, accumulation of sorbitol in certain cells 
results in osmotic stress, which can lead to cell swelling and eventually cell death. 
Inhibitors of aldose reductase can prevent these metabolic and biochemical changes, 
which have been linked to the pathogenesis of diabetic complications. 
 
  
ANTIOXIDANT 
The adverse effects of oxidative stress on human health have become a serious issue. The 
World Health Organization (WHO) has estimated that 80% of the earth’s inhabitants rely 
on traditional medicine for their primary health care needs and most of this therapy 
involves the use of plant extracts and their active components. Under stress, our bodies 
produce more reactive oxygen species (ROS) (e.g., superoxide anion radicals, hydroxyl 
radicals and hydrogen peroxide) than enzymatic antioxidants (e.g., superoxide dismutase 
(SOD), glutathione peroxidase (GPx) and catalase) and non-enzymatic antioxidants (e.g., 
ascorbic acid (vitamin C), tocopherol (vitamin E), glutathione, carotenoids and 
flavonoids). This imbalance leads to cell damage6 and health problems7. A lack of 
antioxidants, which can quench the reactive free radicals, facilitates the development of 
degenerative diseases8, including cardiovascular diseases, cancers9, neurodegenerative 
diseases, Alzheimer’s disease and inflammatory diseases10. One solution to this problem 
is to supplement the diet with antioxidant compounds that are contained in natural plant 
sources11. These natural plant antioxidants can therefore serve as a type of preventive 
medicine. Recent reports indicate that there is an inverse relationship between the dietary 
intake of antioxidant-rich foods and the incidence of human disease12. However, 
synthetic antioxidants such as Butylated Hydroxy Toluene (BHT) and Butylated Hydroxy 
Anisole (BHA) have been widely used as antioxidants in the food industry and may be 
responsible for liver damage and carcinogenesis13. 
 
Antioxidants including phenolic compounds (e.g., flavonoids, phenolic acids and tannins) 
have diverse biological effects such as anti-inflammatory, anti-carcinogenic and anti-
atherosclerotic effects as a result of their antioxidant activity14. 
An antioxidant is a molecule capable of inhibiting the oxidation of other molecules. 
Oxidation is a chemical reaction that transfers electrons from a substance to an oxidizing 
agent. Oxidation reactions can produce free radicals. In turn, these radicals can start chain 
reactions that damage cells. Antioxidants terminate these chain reactions by removing 
free radical intermediates and inhibit other oxidation reactions. They do this by being 
  
oxidized themselves, so antioxidants are often reducing agents such as thiols, ascorbic 
acid or polyphenols15.  
 
Although oxidation reactions are crucial for life, they can also be damaging; hence, plants 
and animals maintain complex systems of multiple types of antioxidants, such as 
glutathione, vitamin C and vitamin E as well as enzymes such as catalase, superoxide 
dismutase and various peroxidases. Low levels of antioxidants or inhibition of the 
antioxidant enzymes, cause oxidative stress and may damage or kill cells. 
As oxidative stress might be an important part of many human diseases, the use of 
antioxidants in pharmacology is intensively studied, particularly as treatments for stroke 
and neurodegenerative diseases. However, it is unknown whether oxidative stress is the 
cause or the consequence of disease. 
 
Reactive oxygen species (ROS) capable of causing damage to DNA has been associated 
with carcinogenesis, coronary heart disease and many other health problems related to 
advancing age16. In low concentrations, synthetic antioxidants are also in use for many 
industrial processes e.g. inhibition of radical formation for preventing premature 
polymerization during processing, storage and transportation of unsaturated monomers. 
They exert their effects by scavenging or preventing the generation of ROS17 which can 
protect the formation of free radicals and retard the progress of many chronic diseases18 
including cancer, neurodegenerative, inflammation and cardiovascular diseases19. 
 
 
 
 
 
 
 
  
CHEMISTRY OF BENZOTHIAZOLE NUCLEUS 
 
Being a heterocyclic compound, Benzothiazole finds use in research as a starting material 
for the synthesis of larger, usually bioactive structures. Its aromaticity makes it relatively 
stable, although as a heterocyclic, it has reactive sites, which allow for functionalization. 
Benzothiazole is a colorless, slightly viscous liquid with a boiling point of 227-2280C. 
The density of Benzothiazole is 1.644 gm/ml and molecular mass is 139.19.  
A huge number of therapeutic agents are Benzothiazole derivatives. During recent years 
there have been some interesting developments in the biological activities of 
Benzothiazole derivatives. These compounds have special significance in the field of 
medicinal chemistry due to their remarkable pharmacological potentialities. 
The small and simple Benzothiazole nucleus is present in compounds involved in 
research aimed at evaluating new products that possess interesting biological activities 
like antidiabetic20, antitumour21, antimicrobial22, antitubercular23, antimalarial24, 
anticonvulsant25, anthelmintic26, analgesic27 and anti-inflammatory activity28. 
Heterocyclic containing the Thiazole moiety are present in many natural products such as 
Bleomycin, Epothilone, Lyngbyabellin A & Dolastatin.  
Substituted 2-arylbenzothiazoles have emerged in recent years as an important 
pharmacophore in non-invasive diagnosis of Alzheimer’s disease. Recently, 
benzothiazole derivatives have been evaluated as potential amyloidal-binding diagnostic 
agents in neurodegenerative disease and as selective fatty acid amide hydrolase 
inhibitors29. 
 
 
 
 
  
CHEMISTRY OF GUANIDINE NUCLEUS 
 
The guanidine group defines properties of many biologically active compounds. 
Synthetic guanidines have found applications in the design of molecular recognition 
devices, sensors and catalysts as well as disinfectants and antiseptics for clinical use, and 
in the manufacture and preservation of industrial products30. Guanidines are among the 
strongest organic bases, which is associated with the charge delocalization via six p-
electrons across the CN3 unit31.  
Guanidine group stem from its unique basicity and it’s planar, fork like structure. The 
guanidine group is capable of forming both electrostatic and directed hydrogen bond 
interactions with polar molecules and anions. Arginine, the only natural amino acid 
bearing the guanidinium functionality, is the most basic of all natural amino acids and has 
the highest proton affinity among amino acids. Since guanidine remains protonated over 
a wide pH range, including physiological pH (the pKa of unsubstituted guanidine is 
13.532 and also possesses a geometry enabling it to align well with carboxylates, 
phosphates, sulfates, nitrates and other anionic groups in water as well as polar 
compounds in organic solvents. 
Guanidine-containing molecules display a wide range of biologically important roles, a 
number of synthetic pharmaceuticals incorporate the guanidine framework as exemplified 
by the influenza inhibitor zanamivir33. In addition, in aqueous media the protonated 
guanidine is highly stable and is at the hear of the formation of selective non-covalent 
associations with anionic complementary groups34. Considering the growing importance 
and applications of guanidine derivatives in the field of medicinal and supramolecular 
chemistry, a continuous synthetic interest has been shown for the conversion of amines to 
the corresponding guanidines35. 
In view of above we are here attempts to fuse Benzothiazole with Guanidinopropionic 
ester for screening of anti-diabetic, antioxidant and antimicrobial activities. 
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Chapter 2 
 
 
 
 
 
 
 
 
 
           Literature Review 
 
  
LITERATURE REVIEW 
2. 1. BENZOTHIAZOLE DERIVATIVES 
2. 1. 1. Anti-diabetic 
Curt D1 et al (2010), series of novel substituted N-{3-[(1, 1-dioxido-1, 2- benzothiazol-3-
yl) (phenyl) amino]propyl} benzamide analogs (1)  were synthesized and evaluated for 
anti-diabetic activity against Kv1.3 ion channel.  
 
(1) 
Gabriel Navarrete-Vazquez2 et al (2009), synthesized 2-arylsulfonylaminobenzothiazole 
derivatives and in vitro inhibitory activities of the synthesized compounds were evaluated 
against protein tyrosine phosphatase 1B (PTP-1B). Among them, Compounds (2) and (3) 
showed good inhibitory activity and in vivo anti- hyperglycemic activity in a type 2 
diabetes mellitus rat model. 
(2)                                                                 (3) 
Hermenegilda Moreno-Dıaz3 et al (2008), synthesized -N-(6-Substituted-1, 3-
benzothiazol-2-yl) benzene sulfonamide derivatives and evaluated for their in vivo anti-
diabetic activity in a non-insulin-dependent diabetes mellitus rat model. Compounds (4) 
and (5) were found to be the most potent and docked into the crystal structure of 11β-
HSD1. 
  
 
(4)                                             (5) 
Michael4 et al (2004), designed a novel series of highly potent and selective (2-
arylcarbamoyl-phenoxy)-acetic acid derivatives and screened for their in vitro enzyme 
inhibitory activity against aldose reductase for treatment of chronic diabetic 
complications. Among them, compound (6) had showed good inhibitory activity.  
 
(6) 
Xiangdong Su5 et al (2006), discovered a series of novel Benzothiazole derivatives and 
their inhibitory activity against 11-HSD1 from human hepatic microsomes measured 
using a radioimmunoassay (RIA) method. The compound (7) showed good inhibitory 
activity. 
 
(7) 
Fariborz Firooznia6 et al (2011), synthesized N-(2-amino-4-methoxy-benzothiazol-7-yl)-
N-ethyl-acetamide derivatives and evaluated for their selectivity against Adenosine A2B  
and A1 receptors for type 2 diabetes. Compound (8) showed an excellent selectivity 
against both receptors. 
  
 
(8) 
Aiko Nitta7 et al (2008), a novel series of 3-amino-N-(4-aryl-1, 1-dioxothian-4-yl) 
butanamides and 3-amino-N-(4-aryltetrahydropyran-4-yl) butanamides were synthesized 
and evaluated as dipeptidyl peptidase IV (DPP-IV) inhibitors. Compound (9) showed 
good inhibitory activity. 
 
(9) 
Nigel Vicker8 et al (2007), discovered a novel Benzothiazole derivatives and screened 
for their activity against 11β-HSD1. Compound (10) showed good inhibitory activity. 
 
(10) 
Richard9 et al (2007), designed a Benzothiazole benzimidazole (S)-isothiazolidinone 
((S)-IZD) derivatives through a peptidomimetic modification of the tripeptide (S)-IZD 
protein tyrosine phosphatase 1B (PTP1B) inhibitor. Among them, compound (11) 
showed good inhibitory activity.  
  
 
(11) 
Alessandro Dondoni10 et al (2003), synthesized a 2-lithiobenzothiazole fused to D-
gluconolactone analogues and screened for their activity against glycosidase enzyme for 
type 2 diabetes. Among them, Compound (12) was the most potent. 
 
(12) 
Guo Hua Jin11 et al (2010), synthesized a series of Benzothiazole and evaluated their 
inhibitory activities for NO production in lipopolysaccharide-activated macrophages by 
the suppression of iNOS protein and mRNA expression. Among them, compound (13) 
was the most potent. 
 
(13) 
Alessandra Ammazzalorso12 et al (2011), synthesized a new series of Benzothiazole 
based N-(phenylsulfonyl) amide analogues and evaluated for their selectivity against 
PPARα receptor. Compound (14) had showed good activity in this series. 
 
 
 
  
                                        
(14) 
Yoshio Ogino13 et al (2008), a novel class of 2-{3-oxospiro [isobenzofuran-1(3H), 40-
piperidin]-10-yl} Benzothiazole analogues have synthesized and screened for their 
selectivity against NPY Y5 receptor.  Among them, compound (15) had showed good 
activity. 
 
(15) 
 
2.1.2 Antioxidant 
Damien Cressier14 et al (2009), discovered a new series of Thiadiazole and Benzothiazole 
derivatives and screened for their antioxidant activity by determining the DPPH and 
ABTS free radical scavenging using simple UV spectroscopic methods. Among them, 
compound (16) posses good activity. 
 
(16) 
Tzvetomira Tzanova15 et al (2009), designed a novel series of benzophenone fused 
Benzothiazole derivatives (17) and screened for their antioxidant activity by FRAP 
method. 
 
(17) 
  
Samir bondock16 et al (2009), a poly functionally substituted heterocyclic incorporating 
Benzothiazole moiety was efficiently synthesized via its reactions with some N-
nucleophiles. Representative compound (18) of the synthesized compounds was found to 
be a potent antimicrobial and antioxidant agents. 
 
(18) 
Meng-Chao Cui17 et al (2010), a novel series of Schiff base derivatives of Benzothiazole 
were synthesized and screened for their antimicrobial and antioxidant activity by DPPH 
method.  Among them, compound (19) was more potent.  
 
(19) 
 
Antimicrobial 
Samir Bondock18  et al (2010),  discovered a new series of Thiazole, Thiophene, Pyrazole 
and other related products containing Benzothiazole moiety and screened for their  
antibacterial activity and antifungal. Among them, compound (20) was the most potent. 
 
(20) 
 
 
  
Sohail Saeed19 et al (2010), synthesized a five series of thiourea derivatives bearing 
Benzothiazole moiety and evaluated for antimicrobial and anticancer activities. In 
preliminary MTT cytotoxicity studies, the thiourea derivative (21) was found to be the 
most potent. 
 
(21) 
Balram Soni20 et al (2010), a novel series of Schiff bases of Benzothiazole derivatives 
were synthesized and screened for their antimicrobial activity. Compound (22) was more 
potent in this series. 
 
(22) 
Barot Hitesh21 et al (2010), synthesized 2-amino-7-chloro-6-fluoro Benzothiazole by 
using 4-fluoro-3-chloroaniline and potassium thiocyanate and screened for antibacterial 
(disc diffusion method) and antioxidant activity (ferric ion reduction method). Compound 
(23) shown promising activity. 
 
(23) 
Prabodh Chander Sharma22 et al (2011), a new series of fluoroquinolones annulated with 
6-substituted-2-aminobenzothiazoles derivatives were synthesized and screened for their 
in vitro antibacterial activity against gram positive organism.  Among them, compound 
(24) was the most potent. 
  
 
(24) 
Taleb23 et  al (2011), reported a imidazo[1,2-a]pyridine and imidazo[2,1-
b][1,3]benzothiazole  and evaluated as antimicrobial agents. Among them, compound 
(25) showed good activity as cefixime. 
 
(25) 
 
2.2 GUANIDINE DERIVATIVES 
2.2.1 Anti-diabetic 
Rajesh Bahekar24 et al (2007), a series of substituted N-(thieno [2, 3-b] pyridin-3-yl)-
guanidine) and N-(1H-pyrrolo [2, 3-b] pyridin-3-yl)-guanidine have synthesized and 
evauated in vitro glucose-dependent insulinotropic activity by using RIN5F (Rat 
Insulinoma cell) based assay. Among them, compound (26) was more potent.  
 
(26) 
 
  
Silvio Cunha25 et al (2001), synthesized N- benzoyl guanidine derivatives by converting 
N-benzoyl thiourea into guanidine by HgCl2 method and evaluated for their anti-diabetic 
activity. Among them, compound (27) was more potent. 
 
(27) 
Dolore’s Edmont26 et al (2000), quinoline carboxyguanidine derivatives were synthesized 
by nucleophillic substitution reaction and evaluated for their in vivo anti- diabetic activity 
in a non-insulin-dependent diabetes mellitus rat model. Among them, compound (28) 
showed good activity. 
 
(28) 
Nimisha Singh27 et al (2011), synthesized a series of 8-(arylidene)-4-(aryl)-5, 6, 7, 8-
tetrahydroquinazolin-2-ylamines and 9-(arylidene)-4-(aryl)-6, 7, 8, 9-tetrahydro-5H-
cycloheptapyrimidin-2-ylamines by the reaction of bis-benzylidene cycloalkanones and 
guanidine hydrochloride in presence of NaH and evaluated against glycosidase and 
glycogen phosphorylase enzymes. Among them, compound (29) showed good activity.  
 
(29) 
  
2.2.2 Antioxidant 
Mathan Sankaran28 et al (2010), a series of novel pyrimido and other fused quinoline 
derivatives were synthesized and screened for their in vitro antioxidant activity against 
radical scavenging capacity using DPPH  and total antioxidant activity by FRAP. Among 
them, compound (30) shown promising antioxidant activity. 
 
(30) 
Jose Marquez29 et al (2008), synthesized a cyclodextrin-derived thiourea and guanidine 
from taurine by the isothiocyanation reaction with thiophosgene in aqueous THF and 
evaluated for their antioxidant activity using DPPH method. Among them, compound 
(31) showed good activity. 
 
(31) 
Maxime Mourer30 et al (2009), para-guanidino ethyl phenol and its analogous were 
synthesized, fully characterized and evaluated as antibacterial agents and antioxidant 
agents. Among them, compound (32) showed good activity. 
 
(32) 
 
 
 
 
 
  
2.2.3 Antimicrobials 
 Karel Palat31 et al (2004), a series of 4-substituted phenylguanidinium derivatives have 
synthesized and evaluated in vitro for antimicrobial activity by the broth micro dilution 
method against representative human pathogenic fungi. Among them, compound (33) 
showed good activity. 
 
(33) 
David Boykin32 et al (2008), a series of triaryl guanidine and N-substituted guanidine 
designed to target the minor groove of DNA were synthesized and evaluated as 
antiprotozoal agents. Among them, compound (34) shown promising activity. 
 
(34) 
Miguel Zarraga33 et al (2008), synthesized 11-guanidinodrimene (35) from drimenol and 
tested against Candida albicans.  
 
(35) 
Ram Lakhan34 et al (2002), synthesized fifteen new 1-aryl-2-amino-3-(4-arylthiazol-2-yl) 
(benzothiazol-2-yl) guanidine analogues and screened for their antimicrobial 
susceptibility by the standard disc diffusion method. Among them, compound (36) 
showed good activity. 
 
(36) 
  
Michel Lagrenee35 et al (2008), synthesized a new corrosion inhibitor, namely, 
polyphosphate guanidine urea copolymer (PGUC). The results showed that the PGUC 
(37) had a broad inhibitory spectrum against bacteria.  
 
(37) 
Huining Xiao36 et al (2008), condensation and polymerization were used in the 
preparation of modified guanidine polymers. The two-step synthesis method increased 
the molecular weight of guanidine polymers. This was found to improve antimicrobial 
activity. 
 
2.3 PROPANOIC ACID DERIVATIVES 
2.3.1 Anti-diabetic 
Agustin Casimiro-Garcia37 et al (2008), a new series of aryl or heteroaryl phenyl 
propanoic acid derivatives have synthesized and screened for their selectivity against 
PPRAα receptor for type 2 diabetes. Among them, compound (38) posses good activity. 
 
(38) 
Makoto Murata38 et al (1999), a new series of 5-[[2-(x-carboxyalkoxy) aryl] methylene]-
4-oxo-2-thioxothiazolidine derivatives were synthesized and evaluated for their potency 
as aldose reductase inhibitors by in vivo and in vitro. The compound (39) shown 
promising inhibitory activity as standard (Zenarestat).             
 
                                
  
 
(39) 
Zhefeng Cai39 et al (2006), synthesized a series of azaindole-a-alkyloxy phenyl propionic 
acid analogues and evaluated for PPAR agonist activities. Structure activity relationship 
has developed for PPARα/β dual agonism. The compound (40) was identified as a potent, 
selective PPARα/β dual agonist. 
 
(40) 
Shawn40 et al (2011), a series of b-substituted 3-(4-aryloxyaryl) propanoic acids have 
prepared and evaluated for GPR40 agonists. The compound (41) shown promising 
activity by in vivo mouse mod 
 
                                                                  (41) 
 
2.3.2 Antioxidant 
Kyriaki Pegklidou41 et al (2010), a series of Pyrrolyl-propionic and butyric-acid 
derivatives  were synthesized and screened for their in vitro aldose reductase inhibitory 
activity and antioxidant activity against radical scavenging capacity using DPPH. Among 
them, compound (42) showed good activity. 
  
 
(42) 
Fernanda42 et al (2010), designed a lipophilic compounds structurally based on caffeic, 
hydrocaffeic, ferulic and hydroferulic acids and screened for their antioxidant activity as 
well as their partition coefficients and redox potentials. Among them, compound (43) 
showed good activity. 
 
(43) 
Rakesh Kumar43 et al (2007), reported a series of N-acetyl-L-tyrosine derivatives and 
screened for their in vitro PPAR agonist and antioxidant activity by DPPH. Among them, 
compound (44) shown promising activity. 
 
(44) 
Barbara Morzyk-Ociepa44 et al (2008),  reported  novel catena-poly[(di-m3-aqua)(h2-:-
m2-indole-3-propionato-O)(m3-indole-3-propionato-O)disodium],[Na2(I3PA)2(H2O)2] 
characterized by X-ray diffraction analysis and infrared and Raman spectroscopic 
methods and screened for their biological activity. 
 
 
 
 
  
2.3.3 Antimicrobials 
Kyriaki Pegklidou45 et al (20O9), a series of Pyrrolyl-propionic and butyric-acid 
derivatives were synthesized and screened for their in vitro antibacterial activity by disc 
diffusion method. Among them, compound (45) had showed good activity. 
 
(45) 
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Chapter 3 
 
 
 
 
 
 
 
 
 
                       
Methodology 
  
METHODOLOGY 
3. 1. RESEARCH ENVISAGED 
Benzothiazole is a versatile heterocyclic compound and shows varied pharmacological 
activities like Anti-tumer1, Anti-diabetic2, Anti-tubercular3, Anti-inflammatory4, 
Analgesic5 and Anti-microbial6. 
Diabetes7 around the world and is one of the major public health challenges of the 21st 
century. The number of cases worldwide in 2000 is estimated to be about 171 million and 
its rise to 366 million in 2030. The World Health Organization (WHO) estimated that, 
diabetes-related deaths will increase by more than 50% in the next 10 decades. Especially 
in upper-middle income countries, diabetes deaths are projected to increase by over 80% 
between 2006 and 2015. This circumstance results that the demand for medical care in 
type 2 diabetes will continue to increase.  
Microbial infections are gaining more attention towards the medicinal chemist. Since 
most of the currently used antibacterials or antibiotics are resistance to the vast of the 
microbes. Hence there is a need to develop a newer antimicrobial agent with multi target 
to combat the problem of resistance. 
Over production of reactive oxygen and nitrogen species (ROS/RNS) leads to lowered 
antioxidant defense and alterations of enzymatic pathways. This contribute to endothelial, 
vascular and neurovascular dysfunction. Over the past decade, there has been substantial 
interest in oxidative stress and its potential role in diabetogenesis, development of 
diabetic complications, atherosclerosis and associated cardiovascular disease. So 
developing compounds containing both anti-oxidant and anti-diabetic activity is a 
relevant adjuvant pharmacotherapy. 
 
 
 
 
  
Keeping on the above consideration and based on literature we synthesize some novel 
analogue. 
 Synthesis of some novel Benzothiazole derivatives bearing Guanido group. 
 The linker group (methenyl and phenyl) have been introduced between 
Benzothiazole and Guanidinopropionic ester. 
 Characterization of synthesized compounds by various analytical techniques like 
TLC, FTIR, H1NMR and Mass Spectral studies. 
BIOLOGICAL SCREENING 
 In vitro Aldose Reductase enzyme inhibition assay technique. 
 Screening for antibacterial activity against bacterial organisms like Micrococcus 
luteus, Staphylococcus aureus, Bacillus subtilies, Cornybacterium diphtheria, 
Bacillus linctus, Escherichia coli, Pseudomonas aureginosa, Rhodosporum 
rubrum and Vibrio cholera by Disc diffusion method and Minimum inhibitory 
concentration (MIC) by serial dilution method. 
 Screening for antifungal activity against fungal organisms like Candida albicans, 
Aspergillus niger, Aspergillus fumigates, Aspergillus parasites by Disc Diffusion 
method and Minimum inhibitory concentration (MIC) by serial dilution method. 
 Screening for antioxidant activity by using in vitro DPPH method. 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
3.2. PLAN OF STUDY 
Phase I 
Scheme 
 
 
Reagents & conditions: (a) NaSCN/Br2, HCl (stir for 2 hrs at 50c); (b) KOH, ZnCl2, H2O 
(reflux for 4 hrs). 
 
 
 
 
 
 
 
 
 
  
 
Series I 
 
 
Reagents & conditions : (c) p- nitro benzoylchloride, C6H5N (stir for 1 hr at 800c); (d) 
SOCl2 (reflux for1 hr); (e) SnCl2, C2H5OH, HCl (heat in water bath for 6 hrs); (f) 50% 
NH4SCN, HCl (heat on steam bath for 3-4hrs); (g) silica gelG, CuSO4.5H2O, β alanine, 
TEA, THF (stir for 5 hrs); (h) ROH, H2SO4 (reflux for 6 hrs). 
 
 
 
 
 
 
 
  
Series II 
 
 
Reagents & conditions: (i) Br-CH2-CO-Br, C6H5N (stir for 2 hrs at 800c); (j) SOCl2 
(reflux for 90 mts); (k) NH3 (heat in water bath for 1 hr); (l) 50% NH4SCN, HCl (heat on 
steam bath for 5-6 hrs); (m) silicagel G, CuSO4.5H2O, β alanine, TEA, THF  (stir for 7 
hrs); (n) ROH, con.H2SO4 (stir for 7 hrs). 
 
 
 
 
 
 
 
 
 
 
  
Phase II 
Characterization: All the newly synthesized compounds will be characterized by 
Melting point determination, Solubility property, TLC analysis and their structure will be 
elucidated by IR- Spectroscopy, H1 NMR Spectroscopy and MASS Spectroscopy.  
Phase III 
Biological evaluation: 
In vitro Aldose reductase enzyme inhibition assay technique: All the synthesized 
compounds will be screened for in-vitro Aldose reductase enzyme inhibition assay 
technique. 
In vitro antimicrobial activity: All the synthesized compounds will be screened for 
antimicrobial activity against various bacteria and fungi by using Disc Diffusion method 
and Minimum Inhibitory Concentration (MIC) method. 
In vitro antioxidant activity: All the synthesized compounds will be evaluated for in 
vitro antioxidant activity by DPPH method. 
 
 
 
 
 
 
 
 
 
  
EXPERIMENTAL 
General Procedure 
Synthesis of 2-aminobenzothiazole-6-carboxylic acid (BC 1)8 
Sodium thiocyanate (65g, 0.8 mol) was added to a suspension of 4-amino-benzoic acid 
(1, 100g, 0.8 mol) in methanol followed by the addition of bromine (38ml, 0.8 mol) in 
portions. The above solutions was allowed to cool at -100C and stirred for 2 hrs while 
keeping the inner temperature below -50C. The precipitate was then filtered and 
suspended in 350 ml of 1M hydrochloric acid and refluxed for 30 min. After immediate 
filtration, 150 ml concentrated hydrochloric acid was added to the hot filtrate to yield a 
white precipitate of 2-aminobenzothiazole-6-carboxylic acid (87g, 75%, m.p: 2020C, Rf = 
0.7 (CHCl3:CH3OH 1:1)). 
Synthesis of Zinc salt of 4-amino-3-mercaptobenzoic acid (BC 2) 
Compound 2-aminobenzothiazole-6-carboxylic acid (BC 1) (9.18g, 40 mmol) was 
dissolved in a potassium hydroxide solution (45g KOH\45 ml water) and refluxed for 3 
hrs. After being cooled to room temperature, the solution was neutralized by concentrated 
hydrochloric acid and aqueous solution of Zinc chloride (0.02mmol in 25 ml of water) 
was added slowly while white solid precipitated out. The suspension was acidified by 
glacial acetic acid. The solid was filtered, washed with water, and dried in a vacuum to 
yield a white precipitate of 4-amino-3-mercaptobenzoic acid (11g, 26%, m.p: 1840C, Rf = 
0.78 (CHCl3:CH3OH 1:1)). 
Series I 
Synthesis of 2-(4’-nitrophenyl)-6-(benzothiazolyl) carboxylicacid (BC 3) 
Compound 4-amino-3-mercaptobenzoic acid (BC 2) (8.18g, 20mmol) was suspended in 
pyridine (50 ml) and heated to 800C. p-nitrobenzoyl chloride (8g, 42.8 mmol) was added 
to that suspension and  stirred for 1 hour. After being cooled to room temperature, the 
precipitate was filtered, washed with dilute hydrochloric acid and water, and dried under 
  
vacuum to yield  2-(4’-nitrophenyl)-6-(benzothiazolyl) carboxylic acid  (7g, 85%, m.p: 
1040C, Rf = 0.72 (CHCl3:CH3OH 1:1)). 
Synthesis of 2-(4-nitro-phenyl)-benzothiazole-6-carbonyl chloride (BC 5) 
Compound 2-(4’-nitrophenyl)-6-(benzothiazolyl) carboxylic acid (BC 3) (1g, 3.3 mmol) 
was suspended in thionyl chloride (5 ml) and refluxed for 1 hr and excess thionyl 
chloride was evaporated under reduced pressure to yield 2-(4-nitro-phenyl)-
benzothiazole-6-carbonyl chloride. (0.9g, 95%, m.p: 1170C, Rf = 0.81 (CHCl3:CH3OH 
1:1)).     
Synthesis of 2-(4-amino-phenyl)-benzothiazole-6-carbonyl chloride (BC 7)  
Compound 2-(4-nitro-phenyl)-benzothiazole-6-carbonyl chloride (BC 5) (7.5g, 0.02mol) 
was dissolved in concentrated hydrochloric acid (13 ml) and ethanol (100 ml) followed 
tin chloride (2g, 10 mmol) was added to that  suspension  and  heated to 80 0C for 5 hrs. 
After being cooled to room temperature, the solid was filtered, washed with concentrated 
hydrochloric acid , water and dilute ammonium and dried in vacuum to get  2-(4-amino-
phenyl)-benzothiazole-6-carbonyl chloride. (6g, 88%, m.p: 1370C, Rf = 0.7 
(CHCl3:CH3OH 1:1)). 
Synthesis of 2-[4-(carbamothioylamino) phenyl]-1, 3-benzothiazole-6-carboxylic acid 
(BC 9)9   
Compound 2-(4-amino-phenyl)-benzothiazole-6-carbonyl chloride (BC 7) (0.02 mol, 
5.78g) was dissolved in concentrated hydrochloric acid (25 ml) and warmed. A saturated 
solution of ammonium thiocyanate (saturated, 50%) in water was added slowly in above 
solution, the mixture was boiled for 3-4 hrs until the solution turns turbid. The turbid 
solution was poured in cold water. The separated phenylthiourea precipitate was filtered 
and crystallized with aqueous ethanol. (7g, 97%, m.p: 1280C, Rf = 0.6 (Toluene: 
Ethylaetate1:2)) 
 
  
Synthesis of 2-{4-[N’-(2-carboxyethyl) carbamimidamido] phenyl}-1, 3-
benzothiazole-6-carboxylic acid (BC 11)10 
β alanine (0.02 mol, 1.78g) was added to the stirring mixture of compound 2-[4-
(carbamothioylamino)phenyl]-1,3-benzothiazole-6-carboxylic acid (BC 9) (0.02 mol, 
6.94g) containing silica gel G (0.01g), cupric sulphate pentahydate (0.01g), triethylamine 
(2 ml) in tetrahydrofuran (25 ml). Stirring was continued for 5 hrs and an excess of 
solvent was evaporated at room temperature and recrystallized with methanol. (3g, 40%, 
m.p: 1670C, Rf = 0.8 (Toluene: Ethylaetate1:2)). 
Synthesis of ester derivative of 2-{4-[N’-(2-carboxyethyl) carbamimidamido] 
phenyl}-1, 3-benzothiazole-6-carboxylic acid (BC 11a – BC 11e) 11 
Compound BC 11 2-{4-[N’-(2-carboxyethyl)carbamimidamido]phenyl}-1,3-
benzothiazole-6-carboxylic acid (0.001mol, 0.3g) was dissolved in respective alcohol 
derivatives (a-ethyl, b-n-butyl, c-iso propyl, d-phenyl, e-tolyl) and an appropriate quantity 
of concentrated sulphuric acid  (2 ml) was added and  refluxed for  5-6 hrs. The reaction 
completion was monitored by thin layer chromatography. 
Series II 
Synthesis of 2-(bromo methyl)-benzothiazole-carboxylic acid (BC 4) 
Compound 4-amino-3-mercaptobenzoic acid (BC 2) (8.18, 20mmol) was suspended in 
pyridine (50 ml) and heated to 80 0C and then bromoacetylbromide (3.7 ml, 42.8 mmol) 
was added in portions to get a clear solution and stirred for 2 hrs. After being cooled to 
room temperature, the precipitate was filtered, washed with dilute hydrochloric acid and 
water, and dried under vacuum to afford 2-(bromo methyl)-6-(benzothiazolyl) carboxylic 
acid. (6g, 55%, m.p: 1400C, Rf = 0.7 (CHCl3:CH3OH 1:1)). 
 
 
 
  
Synthesis of 2-(bromo methyl)-benzothiazole-6-carbonyl chloride (BC 6) 
Compound 2-(bromo methyl)-6-(benzothiazolyl) benzothiazole (BC 4) (0.8g, 3.3 mmol) 
was suspended in thionyl chloride (5 ml) and refluxed for 90 mts. Then excess thionyl 
chloride was evaporated under reduced pressure to get 2-(bromo methyl)-benzothiazole-
6-carbonyl chloride. (0.6g, 75%, m.p: 1380C, Rf = 0.9 (CHCl3:CH3OH 1:1)). 
Synthesis of 2-(amino methyl)-benzothiazole-6-carbonyl chloride (BC 8)12 
To compound 2-(bromo methyl)-benzothiazole-6-carbonyl chloride (BC 6) (2.8g, 
0.01mol) was suspended in ammonia (30 ml) and boiled for 1 hr. After being cooled to 
room temperature, the solid was filtered, and dried in a vacuum to yield 2-(amino 
methyl)-benzothiazole-6-carbonyl chloride. (2g, 71%, m.p: 1050C, Rf = 0.65 
(CHCl3:CH3OH 1:1)). 
Synthesis of 2-[4-(carbamothioylamino) methyl]-1, 3-benzothiazole-6-carboxylic 
acid (BC 10) 
Compound 2-(amino methyl)-benzothiazole-6-carbonyl chloride (BC 8) (0.02 mol, 
4.54g) was dissolved in concentrated hydrochloric acid (25 ml) and warmed. A saturated 
solution of ammonium thiocyanate (saturated, 50%) in water was added slowly in above 
solution, the mixture was boiled for 5-6 hrs until the solution turns turbid. The turbid 
solution was poured in cold water. The separated thiourea precipitate was filtered and 
crystallized with aqueous ethanol. (4g, 88%, m.p: 1190C, Rf = 0.73 (Toluene: Ethylaetate 
1:2)). 
 
 
 
 
 
  
Synthesis of 2-{4-[N'-(2-carboxyethyl) carbamimidamido] methyl}-1,3-
benzothiazole-6-carboxylic acid (BC 12) 
β alanine (0.02 mol, 1.78g) was added to the stirring mixture of compound 2-[4-
(carbamothioylamino)methyl]-1,3-benzothiazole-6-carboxylic acid (BC 10) (0.02 mol, 
5.8g) containing silica gel G (0.01g), cupric sulphate pentahydate (0.01g), triethyl amine 
(2 ml) in tetrahydrofuran (25 ml). Stirring was continued for 6 hrs and an excess of 
solvent was evaporated at room temperature and recrystallized with aqueous methanol. 
(2.5g, 40%, m.p: 1340C, Rf = 0.8 (Toluene: Ethylaetate 1:2)). 
Synthesis of ester derivative of 2-{4-[N'-(2-carboxyethyl) carbamimidamido] 
methyl}-1, 3-benzothiazole-6-carboxylic acid (BC 12a- BC 12e) 
Compound 2-{4-[N'-(2-carboxyethyl) carbamimidamido] methyl}-1, 3-benzothiazole-6-
carboxylic acid (BC 12) (0.001mol, 0.3g) was dissolved in respective alcohol derivatives 
(a-ethyl, b-n-butyl, c-iso propyl, d-phenyl, e-tolyl) and an appropriate quantity of 
concentrated sulphuric acid (2 ml) was added and refluxed for 5-6 hrs. The reaction 
completion was monitored by thin layer chromatography. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
    
                    (BC 11a – BC 11e )                                                                (BC 12a – BC 12e) 
 
Table 1: Physical data of synthesized compounds 
Code R M.F M.W  M.P(0C) Yield (%) Clogp 
BC 11a C2H5 C20H19O3N4SCl 430.90 190 62 3.051 
BC 11b C4H9 C22H23O3N4SCl 458.96 170 58 4.120 
BC 11c 
 
C21H21O3N4SCl 444.93 145 51 3.360 
BC 11d 
 
C24H19O3N4SCl 478.95 * 67 3.761 
BC 11e 
 
C25H21O3N4SCl 492.97 * 75 4.260 
BC 12a C2H5 C15H17O3N4SCl 368.83 95 64 1.337 
BC 12b C4H9 C17H21O3N4SCl 396.89 115 57 2.396 
BC 12c 
 
C16H19O3N4SCl 382.86 130 67 1.647 
BC 12d 
 
C19H17O3N4SCl 416.88 * 78 2.047 
BC 12e 
 
C20H19O3N4SCl 430.90 * 70 2.546 
* Compounds are liquid in state 
All compounds are soluble in DMSO 
 
 
  
3.3. ANALYTICAL WORK 
THE LAYER CHROMATOGRAPHY 
Thin layer Chromatography is a method of analysis in which the stationary phase, a 
finely divided solid, is spread as a thin layer on a rigid supporting plate and the mobile 
phase, a liquid is allowed to migrate across the surface of the plate. 
Applications of TLC 
1. To establish the purity and authenticity of starting materials and reagents. 
2. To monitor the reactions, particularly in the case of new reactions. 
3. Assessment of purity of a crude reaction product. 
4. The optimum of experimental conditions to achieve the highest possible yield of 
product. 
Provided that the experimental conditions are reproducible, the movement of any 
substance relative to the solvent front in a given chromatographic system is constant and 
characteristic of the substance. The constant is called as retardation factors (Rf) and is 
defined as 
Rf    =   Distance travelled by solute 
                         Distance traveled by the solvent front 
True reproducibility in Rf value is, however, rarely achieved in practice due to minor 
changes in a number of variables such as: 
a. The particle size of different batches of adsorbent. 
b. The solvent composition and the degree of saturation of the chamber 
atmosphere with solvent vapor. 
c. Prior activation and storage conditions of the plates. 
d. The thickness of adsorbent layer, etc. 
It is therefore, not desirable to use Rf value in isolation as a criteria for identity. 
 
  
TLC were performed as following procedure 
  Dimension of plates  : 5*20cm 
  Stationary phase  : Silica gel-G 9E-merck 
  Mobile phase   : Chloroform: Methanol (1:1) 
  Technique   : Ascending 
  Detection Method  : UV chamber at 254nm 
Preparation of Plates  
Uniform slurry of silica get G was prepared by addition of distilled water. This was then 
poured into a spreading through and drawn across a series of glass plates of size 5*20cm, 
depositing a uniform layer of stationary phase of 0.25mm thickness. The plates were air 
dried and then activated by heating at 110 0C for one hour. The plates were stored over 
desiccators until used. 
Mobile Phase 
Evaluation of various mobile phases was tried alone or in combination for each 
compound in which Chloroform: Methanol (1:1) was found to be suited. 
Sample Application and Development 
The samples were applied as small spot at about 2cm form the base of the plate. For 
ascending development of the thin layer chromatogram, the plate was placed in a TLC 
Chamber, which was saturated with mobile phase containing the developing solvent to a 
depth of about 0.5cm. The solvent was allowed to move up the plate until it travelled a 
distance of about 15cm from the point of the sample, on a 20cm plate. The plate was then 
removed from the chamber, the solvent front was marked by scratching the surface and 
the plate was allowed to be evaporated. 
           
 
  
Detection 
After the chromatogram was developed the solute sports need to be made visible in order 
to determine their Rf values. UV chamber was employed for the detection of the 
compounds by placing the plate in a chamber at short wavelength (254nm).The solute 
was visible as blue spot. 
 
 
                                    Table 2:   Rf value of synthesized compounds 
 
S.NO Compound Rf value 
1 BC 11a 0.91 
2 BC 11b 0.73 
3 BC 11c 0.84 
4 BC 11d 0.88 
5 BC 11e 0.90 
6 BC 12a 0.80 
7 BC 12b 0.78 
8 BC 12c 0.81 
9 BC 12d 0.79 
10 BC 12e 0.84 
 
 
 
 
 
 
 
 
  
3.4. INFRARED SPECTRAL STUDY 
The range of electromagnetic radiation between 0.8 and 500µm is referred as infrared 
radiation. The IR spectrum is represented with percent transmittance as the ordinate and 
the wave number (cm-1) as the abscissa. The most commonly used region of IR spectrum 
in pharmaceutical chemistry is between 2.5µm (400cm-1) and 16µm (625cm-1). Two 
major applications of IR spectrometry are characterization of various molecules includes 
Determination of identity of a compound by means of spectral comparison with that of 
authentic sample. 
Verification of the presence of functional groups in unknown molecules which is quite 
important in the structural elucidation of synthetic organic compounds or substances 
isolated from natural sources. Samples were prepared by KBr Disc method. Solid 
samples (0.5-1.Omg) were intimately mixed with powdered potassium bromide. Mixing 
was effected through grinding in a smooth agate mortar and the mixture pressed between 
a punch and disc under the presence   of 1, 00,000-15,000 psi into a transparent disk. The 
infrared spectral study was done on JASCO FTIR 4100. All absorption values are 
expressed in wave numbers cm-1 
The spectral data are given as follows.  
Table-3 
 
Code Absorbance(cm-1) 
 
Groups  
BC 1 3400.01 
3127.01 
1706.07 
1605.45 
1635.07 
670.14 
Primary amine -N-H stretch 
Carboxylic acid -O-H stretch 
Carboxylic acid -C=O stretch 
Aromatic -C=C-  ring stretch 
Cyclic imino -C=N- stretch 
Thiol -C-S stretch 
 
BC 2  3300.02 
 3127.01 
1706.69 
1609.31 
1247.72 
 
Primary amine -N-H stretch 
Carboxylic acid -O-H stretch 
Carboxylic acid -C=O stretch 
Aromatic -C=C-  ring stretch 
Primary amine -C-N- stretch 
 
BC 3 3118.33 Carboxylic acid -O-H stretch 
  
1691.67 
1603.53 
1523.31 
 
Carboxylic acid -C=O stretch 
Aromatic -C=C-  ring stretch 
Aromatic –N=O stretch 
 
BC 4 3118.33 
2895.07 
1691.67 
1525.65  
1150.02 
700.29 
 
Carboxylic acid -O-H stretch 
Methylene -C-H stretch 
Carboxylic acid -C=O stretch 
Aromatic -C=C- ring stretch 
CH2X, -C-H stretch 
Aliphatic -C-Br stretch 
 
BC 5 1800.01 
1609.67 
1501.03 
1376.55 
850.02 
Acid chloride -C=O stretch 
Aromatic -C=C-  ring stretch 
Aromatic -N=O stretch 
Aromatic -N=O stretch 
Acid chloride -C-Cl stretch 
 
BC 6 2895.07 
1800.01 
1602.56 
850.03 
700.14 
670.14 
Methylene -C-H stretch 
Acid chloride -C=O stretch 
Aromatic -C=C- ring stretch 
Acid chloride -C-Cl stretch 
Aliphatic -C-Br stretch 
Thiol -C-S stretch 
 
BC 7 3127.97 
1603.52 
850.03 
670.14 
Primary amine -N-H stretch 
Aromatic -C=C- stretch 
Acid chloride -C-Cl stretch 
Thiol -C-S stretch 
 
BC 8 3127.97 
2895.07 
850.03 
669.17 
Primary amine -N-H stretch 
Methylene -C-H stretch 
Acid chloride -C-Cl stretch 
Thiol -C-S stretch 
 
BC 9 3127.97 
2073.16 
1600.63 
1322.93 
670.14 
Primary amine -N-H stretch 
R-N=C=S stretch 
Aromatic -C=C- in ring stretch 
Ar-N stretch 
Thiol -C-S stretch 
 
BC 10 3135.69 
2895.03 
2073.16 
                1618.95 
1546.63 
1262.18 
Primary amine -N-H stretch 
Methylene -C-H stretch 
R-N=C=S stretch 
R-N-H stretch 
Disulfide -C=S stretch 
Aliphatic amine -C-N stretch 
  
668.21 Thiol -C-S- stretch 
 
BC 11 3353.61 
3125.08 
2890.01 
1723.01 
1630.04 
1619.91 
1400.07 
 
Secondary amine -N-H stretch 
Carboxylic acid -O-H stretch 
Methylene -C-H stretch 
Carboxylic acid-C=O stretch 
Imino -C=N- stretch 
Aromatic -C=C- in ring stretch 
Methylene -C-H bend 
 
BC 12 3350.71 
3127.01 
1725.98 
1640.01 
1596.77 
1400.07 
 
Secondary amine -N-H stretch 
Carboxylic acid -O-H stretch 
Carboxylic acid -C=O stretch 
Imino -C=N- stretch 
Aromatic -C=C- in ring stretch 
Methylene -C-H bend 
 
BC 11a 3300.01 
2953.01 
2853.03 
1800.00 
1750.01 
1600.04 
 
Secondary amine -N-H stretch 
Methyl -C-H stretch 
Methylene -C-H stretch 
Acid chloride -C=O stretch 
Aliphatic ester -C=O stretch 
Aromatic -C=C- ring stretch 
BC 11b 3354.44 
2950.04 
2800.01 
1750.01 
1600.02 
720.01 
 
Secondary amine -N-H stretch 
Methyl -C-H stretch 
Methylene -C-H stretch 
Aliphatic ester -C=O stretch 
Aromatic -C=C- ring stretch 
Straight chain alkane 
BC 11c 3347.57 
1700.02 
1600.03 
  1425.04 
1380.01 
Secondary amine -N-H stretch 
Aliphatic ester -C=O stretch 
Aromatic -C=C- ring stretch 
Methyl -C-H bend 
Isopropyl group 
 
BC 11d 3122.19 
1770.01 
1650.77 
1519.63 
Secondary amine -N-H stretch 
Phenol ester -C=O stretch 
Imino -C=N- stretch 
Aromatic -C=C- stretch 
 
BC 11e 3161.72 
1776.65 
1632.45 
1610.01 
Secondary amine -N-H stretch 
Esters -C=O stretch 
Imino -C=N- stretch 
Aromatic -C=C- ring stretch 
  
 
 
 
 
 
 
 
 
 
 
 
 
1422.01 Methyl  -C-H stretch 
 
BC 12a 3353.36 
2956.01 
2850.88 
1750.02 
1600.01 
Secondary amine -N-H stretch 
Methyl -C-H stretch 
Methylene -C-H stretch 
Aliphatic ester -C=O stretch 
Aromatic -C=C- ring stretch 
 
BC 12b 3383.26 
2950.03 
2850.01 
1700.02 
720.03 
Secondary amine -N-H stretch 
Methyl -C-H stretch 
Methylene -C-H stretch 
Aliphatic ester -C=O stretch 
Straight chain alkyl group 
 
BC 12c 3359.14 
2956.01 
2849.92 
1750.02 
1450.03 
1350.01 
Secondary amine -N-H stretch 
Methyl -C-H stretch 
Methylene -C-H stretch 
Aliphatic ester -C=O stretch 
Methyl -C-H bend 
Isopropyl group 
 
BC 12d 3135.69 
1720.01 
1650.77 
1618.95 
Secondary amine -N-H stretch 
Esters -C=O stretch 
Imino -C=N- stretch 
Aromatic -C=C-  ring stretch 
 
BC 12e 3375.18 
1776.65 
1632.45 
1610.01 
1422.01 
Secondary amine -N-H stretch 
Esters -C=O stretch 
Imino -C=N- stretch 
Aromatic -C=C- ring stretch 
Methyl  -C-H stretch 
 
  
 
 
Fig 1: IR spectrum of compound BC 1 
 
 
 
 
Fig 2: IR spectrum of compound BC 2 
 
 
 
 
 
 
  
 
 
Fig 3: IR spectrum of compound BC 3 
 
 
 
 
Fig 4: IR spectrum of compound BC 4 
 
 
 
 
 
 
  
 
 
Fig 5: IR spectrum of compound BC 5 
 
 
 
 
 
Fig 6: IR spectrum of compound BC 6 
 
 
 
 
 
 
  
 
 
 
Fig 7: IR spectrum of compound BC 7 
 
 
 
 
 
Fig 8: IR spectrum of compound BC 8 
 
 
 
  
 
 
Fig 9: IR spectrum of compound BC 9 
 
 
 
 
 
Fig 10: IR spectrum of compound BC 10 
 
 
 
 
  
 
 
Fig 11: IR spectrum of compound BC 11 
 
  
 
 
 
Fig 12: IR spectrum of compound BC 12 
 
 
  
 
Fig 13: IR spectrum of compound BC 11a 
 
 
Fig 14: IR spectrum of compound BC 11b 
  
 
Fig 15: IR spectrum of compound BC 11c 
 
 
 
 
Fig 16: IR spectrum of compound BC 11d 
 
 
 
 
  
 
 
Fig 17: IR spectrum of compound BC 11e 
 
 
 
 
Fig 18: IR spectrum of compound BC 12a 
  
 
Fig 19: IR spectrum of compound BC 12b 
 
 
 
Fig 20: IR spectrum of compound BC 12c 
  
 
 
 
Fig 21: IR spectrum of compound BC 12d 
 
 
 
 
Fig 22: IR spectrum of compound BC 12e 
 
 
 
 
  
3.5. NUCLEAR MAGNETIC RESONANCE SPECTROMETRY 
Nuclear magnetic spectrometry is an important tool for determining the structures of a 
molecule. NMR spectrum can give almost unbelievable detailed information about 
molecular structure: 
a. The number of signals: which tell us how many different kinds of 
protons there are in a molecule. 
b.  The positions of the signals, which tell us something about the 
electronic environment of each kind of proton. 
c. The intensities of the signals, which tell us how many protons of each 
kind there are; and the splitting of a signal into several peaks, which 
tell us about the environment of a proton with respect to other, nearby 
protons. NMR spectral study was done on Burker Fourier, Transform-
NMR Spectrometer on selected compounds 
 
BC11a: ethyl-3-(N’-{4-[6-(chlorocarbonyl)-1, 3-benzothiazol-2-yl] phenyl} 
carbamimido) propanoate 
 
8.39-8.20 (m, 3H, ArH in Benzothiazole) 
7.95 (d, 4H, ArH in phenyl) 
5.12 (s, 1H, NH) 
3.41 (s, 1H, NH) 
2.50 (s, 2H, CH2 in ester) 
1.32-1.19 (t, 2H, CH2) 
0.85 (s, 3H, CH3) 
  
BC 11c:  isopropyl-3-(N’-{4-[6-(chlorocarbonyl)-1,3-benzothiazol-2-yl] phenyl} 
carbamimido)propanoate 
 
8.40-8.19 (m, 3H, ArH in Benzothiazole) 
7.94-6.90 (d, 4H, ArH in phenyl) 
4.30 (s, 1H, NH) 
4.34-4.28 (m, 1H, CH) 
3.70 (q, 2H, CH2) 
2.50-2.42 (t, 2H, CH2) 
1.34-1.09 (d, 6H, CH3) 
 
BC 11d: phenyl-3-(N’-{4-[6-(chlorocarbonyl)-1, 3-benzothiazol-2-yl] phenyl} 
carbamimido) propanoate 
 
7.06-6.97 (m, 3H, ArH in Benzothiazole) 
6.82-6.60 (d, 4H, ArH in phenyl) 
6.70-6.67 (m, 5H, ArH in phenyl) 
3.61 (s, 1H, NH) 
2.14-2.16 (t, 2H, CH2) 
 
 
  
BC 11e: 2-methyl phenyl-3-(N’-{4-[6-(chlorocarbonyl)-1, 3-benzothiazol-2-yl] 
phenyl} carbamimido) propanoate 
 
7.28-7.26 (m, 3H, ArH in Benzothiazole) 
7.04-6.95 (d, 4H, ArH in phenyl) 
6.70-6.67 (m, 4H, CH in tolyl) 
4.36 (s, 1H, NH) 
2.51-2.50 (t, 2H, CH2) 
2.2-2.1 (s, 3H, CH3) 
 
BC 12d: phenyl-3-(N’-{4-[6-(chlorocarbonyl)-1, 3-benzothiazol-2-yl] methyl} 
carbamimido) propanoate 
 
7.70-7.13 (m, 3H, ArH in Benzothiazole) 
6.91-6.72 (m, 5H, ArH in phenyl) 
2.60-2.50 (d, 2H, CH2) 
 
 
 
  
BC 12e: 2-methyl phenyl-3-(N’-{4-[6-(chlorocarbonyl)-1, 3-benzothiazol-2-yl] 
methyl} carbamimido) propanoate 
 
7.17-7.14 (m, 3H, ArH in Benzothiazole) 
6.77-6.74 (m, 4H, ArH in tolyl) 
3.70-3.40 (d, 2H, CH2) 
2.50-2.30 (s, 3H, CH3 
 
 
 
 
Fig 23: 1HNMR spectrum of compound BC 11a 
 
 
  
 
 
 
 
 
 
 
Fig 24: 1HNMR spectrum of compound BC 11c 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Fig 25: 1HNMR spectrum of compound BC 11d 
  
 
 
 
 
 
 
Fig 26: 1HNMR spectrum of compound BC 11e 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
Fig 27: 1HNMR spectrum of compound BC 12d 
 
 
 
 
  
 
 
 
  
 
 
 
Fig 28: 1HNMR spectrum of compound BC 12e 
 
 
 
 
 
 
 
  
 
3.6. MASS SPECTROSCOPY 
In the technique of mass spectroscopy, the compound under investigation is bombarded 
with a beam of electrons which produce an ionic molecule or ionic fragments of the 
original species. The resulting assortment of charged particles is then separated according 
to their masses. The spectrum produced, known as mass spectrum is a record of 
information regarding various masses produced and their relative abundance. 
The mass spectra of selective compounds were recorded on JEOL GCMATE instrument. 
                                                         
Table 4 
S.NO Compound code Molecular 
mass(m\z) 
Base peak [M+2] peak 
1 BC 11d 478.60 251.39 480.02 
2 BC 12e 430.34 251.34 432.01 
 
 
 
 
  
 
Fig 29: Mass spectrum of compound BC 11d 
 
 
 
 
Fig 30: Mass spectrum of compound BC 12e 
 
 
 
 
  
3.7. IN-VITRO ALDOSE REDUCTASE ENZYME INHIBITON ASSAY 
TECHNIQUE13, 14  
Procedure: 
The Aldose reductase enzyme was purchased from the Sigma-Aldrich. The AR activity 
was spectrophotometrically assayed by measuring the decrease in NADPH absorption at 
340 nm over a 4 min period, using DL-glyceraldehyde as a substrate. Each 1.0 ml cuvette 
containing equal units of enzyme, 0.1M sodium phosphate buffer (pH 6.2), 0.3 mM 
NADPH either with or without 10 mM substrate and inhibitor (10µg) was prepared. One 
set of mixtures prepared with an equivalent volume of sodium phosphate buffer instead 
of tested samples was used as control. The concentration of the sample required to inhibit 
50% of ΑR activity under the assay conditions was defined as the IC50 value. Epalrestat 
was used as a standard drug. Inhibitory concentration (IC50) was calculated by using the 
following formula. 
 
IC50 = (1-A|B) × 100 
                                            Where, A= Absorbance of sample 
                                             B= Absorbance of control 
 
 
 
 
 
 
 
 
  
           
     
Table 5: In vitro Aldose reductase inhibitory activity data of synthesized compounds 
S.N Compounds Absorbance Ic50 (%) 
1 BC 11a 1.4872 26 
2 BC 11b 1.5812 21 
3 BC 11c 1.4015 30 
4 BC 11d 0.6532 59 
5 BC 11e 0.7563 53 
6 BC 12a 1.4225 29 
7 BC 12b 1.5581 22 
8 BC 12c 1.5779 31 
9 BC 12d 0.3235 80 
10 BC 12e 0.5063 68 
11 Epalrestat 0.2012 90 
  
 
 
  
3.8. DOCKING STUDIES WITH ALDOSE REDUCTASE15 
Procedure: 
Molecular Operating Environment (MOE) 200716 was used for ligand and protein 
preparation and molecular structure viewing. The crystal structure of Aldose reductase 
was obtained from the Protein Data Bank with the accession code 2BGQ. Docking 
calculations were conducted with AUTODOCK 4.1 In short; AUTODOCK performs an 
automated docking of the ligand with user-specified dihedral flexibility within a protein 
rigid binding site. The program performs several runs in each docking experiment. Each 
run provide some predicted binding mode. All water molecules, zinc atom, ligand were 
removed from the Protein Data Bankfile. Polar hydrogen atoms were added and Kollman 
charges, atomic salvation parameters and fragmental volumes were assigned to the 
protein. For validation of the docking protocol, ligand coordinates in the crystal complex 
were removed. For ligand (BC 12d), gasteiger charges were assigned and non-polar 
hydrogen atoms were merged. All torsions were allowed to rotate during docking. The 
auxiliary program Auto Grid generated the grid maps. Lennard-Jones parameters 12–10 
and 12–6, supplied with the program, were used for modeling H-bonds and van der 
Waals interactions, respectively. The distance-dependent dielectric permittivity of Mehler 
and Solmajer was used for calculation of the electrostatic grid maps. For ligand, random 
starting positions, random orientations and torsions were used. The translation, 
quaternion and torsions steps were taken from default values in AUTODOCK. The 
Lamarckian genetic algorithm and the pseudo-Solis and Wets methods were applied for 
minimization using default parameters. The number of docking runs was 10. After 
docking, the 10 solutions were clustered into groups with RMS lower than 1.0 Å. The 
clusters were ranked by the lowest energy representative of each cluster. In order to 
describe the ligand-binding pocket interactions, the top ranked binding mode found by 
AUTODOCK in complex with the binding pocket of Aldose reductase was subject to full 
energy minimization using the MMFF94 force field implemented in MOE until the 
gradient 0.05 was reached. During minimization, residue atoms within 8 Å from the 
ligand were free to move (other atoms were fixed). 
 
  
 
 
 
 
 
 
 
 
Fig 31: Predicted binding mode of BC 12d into the catalytic site of AR. Amino acid 
residues to the binding pocket of ligand (2.25 Å) are labeled 
 
 
 
 
 
                                                                                                                                                            
  
3.9. IN-VITRO ANTIMICROBIAL STUDIES17 
The in vitro antibacterial activity of the series of synthesized compounds was evaluated 
against 9 pathogenic bacteria and 4 pathogenic fungi. The bacteria and fungus strains 
were procured from the bacterial repository of department of biotechnology, KMCH 
College of Pharmacy, Coimbatore. 
Dimethyl sulphoxide was used to prepare stock solution of standard and synthesized 
drugs. Subsequent dilutions of the stock were also made with above solvent. Muller 
Hinton agar media (hi-media) for bacteria and Sabourand’s Dextrose Broth for fungus 
were used to subculture various strain of bacteria and fungus as well for determining the 
MIC’s of synthesized compounds by serial dilution method.  
3.9.1. DISC DIFFUSION METHOD 
The disc diffusion method, the drug potency is based on measurement of the diameter of 
zone of inhibition surrounding cylinder disc which are placed on the surface of a nutrient 
medium previously inoculated with a culture of suitable microorganisms. Inhibition 
produced by the test compound is compared with that produced by known concentration 
of reference standard ascorbic acid. 
List of bacterial and antifungal strains used  
Bacteria 
1. Micrococcus luteus (Gram positive) 
2. Staphylococcus aureus (Gram positive) 
3. Corny bacterium diphtheria (Gram positive) 
4. Bacillus subtilis (Gram positive) 
5. Bacillus lintus (Gram negative) 
6. Escherichia coli (Gram negative) 
7. Pseudomonas aeruginosa (Gram negative) 
8. Rhodosporium rubrum (Gram negative) 
9. Vibrio cholera (Gram negative) 
  
Fungus 
1. Candida albicans 
2. Aspergillus niger 
3. Aspergillus fumigates 
4. Aspergillus parasites 
 3.9.1. a. Antibacterial screening 
The antibacterial activities of synthesized compounds were screened in the concentration 
of 0.1mg in dimethyl sulphoxide against the above mentioned bacteria in the Muller 
Hinton agar medium by Disc diffusion method using ciprofloxacin as standard. The 
antibacterial activity was evaluated by measuring zone of inhibition in mm. the procedure 
is given below. 
PROCEDURE 
Preparation of Nutrient Broth for Bacteria 
 Ingredients used 
 
 
 
          
 
 
 
 
 
The accurately weighed quantity of above ingredients were transferred to a conical flask, 
and dissolved in distilled water with the aid of heat with stirring and the pH was adjusted 
to 7.2 – 7.4 and plugged with non-absorbent cotton, covered by Aluminum foil and 
sterilized by autoclaving (1210C at 15 Ibs pressure for 15 min). 
 
S.N Ingredients Quantity 
1 Beef extract 10g 
2 Peptone 10g 
3 Sodium chloride 5g 
4 Water 1000ml 
  
Preparation and standardization of inoculation 
Each bacterial pure culture from the slant culture is picked up aseptically and was 
transferred into 100 ml of nutrient broth. The inoculated broths were incubated at 370C 
for 24 hrs and growth was arrested by stored in the refrigerator (below 40C). 
Sample Preparation 
 0.9mg of each sample was dissolved in 1ml DMSO (Dimethyl sulphoxide). The solvent 
control shows no antibacterial activity with all the test organisms used. The sterile disc (6 
mm in diameter) were impregnated with 100 µg/disc of the sample and tested against 
microbial cultures. 
Media used (Muller-Hinton Agar Medium, Hi-media India (Pvt) Ltd) 
 Muller Hinton agar medium was prepared and transferred into sterile Petri plates 
aseptically (thickness of 5-6mm). The plates were allowed to dry at room temp. The 
plates were inverted to prevent condensate falling on the agar surface. The layers of the 
medium are uniform in thickness, is done by placing the plates on a leveled surface. 
Standardized bacterial inoculums were applied to the plates and spreaded uniformly over 
the surface of medium by using a sterile Non-absorbent cotton swab and finally the swab 
was passed around the edge of the medium. The inoculated plates were closed with the 
lid and allowed to dry at room temperature. The sample impregnated discs were placed 
on the inoculated agar medium. All Petri plates were incubated at 370C for 24 hrs. After 
the incubation diameter of zone of inhibition produced by the sample were measured. 
(Table-6, Fig-(32 to 34)) 
3.9.1. b. Antifungal screening 
 The antifungal activities of synthesized compounds were screened in the concentration 
of 0.1mg in dimethyl sulphoxide against the above mentioned fungus in the Sabourand’s 
Dextrose Agar medium by Disc diffusion method using Clotrimazole as standard. The 
antifungal activity was evaluated by measuring zone of inhibition in mm. The procedure 
is given below. 
  
PRCEDURE 
Preparation of Sabourand’s Dextrose Broth for Fungi 
Ingredients used 
S.N Ingredients Quantity 
1 Dextrose 40g 
2 Peptone 10g 
3 Water 1000ml 
 
Specified amount of peptone and dextrose was taken along with 1000ml of distilled water 
in a conical flask and heated in a steam bath to dissolve. The pH was maintained at 7.6 ± 
0.2 and sterilized in an autoclave at 15 lb pressure, 1200C for 15 minutes. The sterile 
medium was poured into the Petri dish and allowed to solidify. 
Preparation and standardization of inoculums 
Each fungal pure culture from the slant culture is picked up aseptically and was 
transferred into 100ml of nutrient broth. The inoculated broths were incubated at 270C-
280C for 24-48 hrs and growth was arrested by stored in the refrigerator (below 40C). 
Sample preparation 
 0.4mg of each sample was dissolved in 0.5ml DMSO (Dimethyl Sulphoxide). The 
solvent control shown no antibacterial activity with all the test organisms used. The 
sterile disc (6 mm in diameter) were impregnated with 100µg/disc of the sample and 
tested against microbial cultures.  
 
 
 
  
Media Used 
 Sabourand’s Dextrose Agar medium, Hi-media India (Pvt) Ltd 
Sabourand’s dextrose Agar medium was prepared and transferred into sterile petriplates 
aseptically (thickness of 5-6mm). The plates were allowed to dry at room temp. The 
plates were inverted to prevent condensate falling on the agar surface. The layers of the 
medium are uniform in thickness, is done by placing the plates on a leveled surface. 
Standardized bacterial inoculums were applied to the plates and spreaded uniformly over 
the surface of medium by using a sterile Non-absorbent cotton swab and finally the swab 
was passed around the edge of the medium. The inoculated plates were closed with the 
lid and allowed to dry at room temperature. The sample impregnated discs were placed 
on the inoculated agar medium. All Petri plates were incubated at 270C-280C for 24 hrs. 
After the incubation diameter of zone of inhibition produced by the sample were 
measured. (Table-8, Fig-35) 
3.8.2. MINIMUM INHIBITORY CONCENTRATION (MIC) 
The lowest concentration of the test compound that completely inhibited growth on agar 
plates, disregarding a singly colony or a faint haze caused by the inoculums was 
considered as minimum inhibitory concentration (MIC) of that compound. 
The potency of drug is based on inhibition of microbial growth as indicated by 
measurement of turbidity of a suspension of a suitable microorganism in a fluid medium 
to which graded amount of test compound have been added. The changes in turbidity 
produced by known concentration of reference materials are compared with results. 
Determination of Minimum Inhibitory Concentration for Synthesized Compounds (MIC) 
by serial dilution Method: 
1. The serial dilutions of known concentration of compound solution were made 
from the stock (0.1 mg/ml) by using Muller Hinton broth using the method 
described below. 
  
2. The tubes were labeled 1 to 8 and 1 ml of Muller Hinton broth were added to the 
first 5 tubes and 8th tube, then added 0.5 ml Muller Hinton broth to 6th and 7th 
tubes. 
3. One ml of different synthesized compounds was added to the 1st tube, mixed and 
transfers 1 ml serially up to tube 5. From the 5th tube transfer 1ml to 6th tube. 
Mixed and transfer 0.5 ml to the 7th tube. Each tube, 1 to 7 contains 1ml diluted 
extract. 
4. 8th tube was the control. 
5. With a standardized micro pipette, added a drop of the diluted broth culture 
approximately 0.01ml of the test organism to all tubes, including the control, 
gently mixed and incubated at 37 0C for 16 to 18hrs. 
6. The highest dilution of particular compounds showing no turbidity was observed 
and recorded. This was taken as the end point, and this dilution was considered to 
contain the concentration of drug equivalent to MIC. (Table-7, Table-9). 
 
  
3.9.3. RESULT  
ANTI-BACTERIAL SCREENING [DISC DIFFUSION METHOD] 
Table 6: Anti-bacterial activity of the synthesized compounds 
S.N Micro organism Zone of Inhibition (in mm) 
BC11a BC11b BC11c BC11d BC11e BC12a BC12b BC12c BC12d BC12e STD 
1 Micrococcus luteus 11 12 11 14 15 13 13 12 15 14 15 
2 Bacillus linctus 12 10 11 15 14 10 11 9 14 15 17 
3 Staphylococcus aureus 11 11 12 15 13 9 9 10 13 13 16 
4 Bacillus subtilis 12 13 13 14 14 11 8 10 13 14 15 
5 Salmonella paratyphi 10 11 13 15 14 11 9 9 15 14 15 
6 Pseudomonas aureginosa 12 12 12 14 15 10 8 9 16 15 18 
7 Klebseilla pneumonia 11 10 13 14 15 13 12 10 14 15 15 
8 Vibrio cholera 9 12 12 13 14 12 11 11 13 13 16 
9 Escherichia coli 12 11 11 15 13 12 12 10 13 14 15 
STD: ciprofloxacin (5µg\disc)                                                                                                                                                                                   
  
SERIAL DILUTION METHOD 
Table 7: MIC values of the synthesized compounds  
S.N Micro organism MIC values (µg/ml) 
BC11a BC11b BC11c BC 11d BC11e BC12a BC12b BC12c BC12d BC12e STD 
1 Micrococcus luteus 50 25 25 12.5 12.5 25 25 25 12.5 12.5 1.25 
2 Bacillus linctus 25 50 25 12.5 12.5 25 25 50 12.5 12.5 3.25 
3 Staphylococcus aureus 25 25 12.5 12.5 12.5 50 50 25 12.5 12.5 1.56 
4 Bacillus subtilis 25 12 12.5 12.5 12.5 25 50 50 12.5 12.5 2.01 
5 Salmonella paratyphi 50 25 12.5 12.5 12.5 25 50 50 12.5 12.5 1.08 
6 Pseudomonas aureginosa 25 25 25 12.5 12.5 50 50 50 12.5 12.5 1.03 
7 Klebseilla pneumonia 50 50 12.5 12.5 12.5 125 25 50 12.5 12.5 1.56 
8 Vibrio cholera 50 25 25 12.5 12.5 25 25 25 12.5 12.5 1.56 
9 Escherichia coli 25 25 25 12.5 12.5 25 25 50 6.25 6.25 1.06 
STD: ciprofloxacin (100µg\ml)  
  
 
 
 
ANTI-FUNGAL SCREENING [DISC DIFFUSION METHOD] 
Table 8: Anti-fungal activity of the synthesized compounds  
S.N Micro organism Zone of inhibition (in mm) 
BC11a BC11b BC11c BC11d BC11e BC12a BC12b BC12c BC12d BC12e STD 
1 Candida albicans 5 4 8 9 12 7 6 10 12 9 12 
2 Aspergillus niger 6 5 7 10 13 8 8 7 13 9 13 
3 Aspergillus fumigates 5 6 6 9 12 6 7 5 12 10 12 
4 Aspergillus parasites 6 7 6 8 13 8 7 8 11 12 13 
STD- Clotrimazole (5µg\disc) 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
SERIAL DILUTION METHOD 
Table 9: MIC values of the synthesized compounds 
S.N Micro organism MIC values (µg/ml) 
BC11a BC11b BC11c BC11d BC11e BC12a BC12b BC12c BC12d BC12e STD 
1 Candida albicans 100 100 25 12.5 6.25 50 50 25 12.5 25 1.9 
2 Aspergillus niger 50 100 25 12.5 6.25 25 25 50 6.25 12.5 1.9 
3 Aspergillus fumigates 100 50 50 25 12.5 50 25 50 12.5 12.5 2.6 
4 Aspergillu .parasites 50 25 50 25 12.5 25 25 25 6.25 6.25 1.5 
STD- Clotrimazole (100µg\ml) 
 
 
 
 
  
 
ANTIBACTERIAL ACTIVITY 
 
Micrococcus luteus (Gram positive) 
 
Staphylococcus aureus (Gram positive) 
 
Corny bacterium diphtheria (Gram positive) 
Fig: 32 
 
  
 
  
Bacillus subtilis (Gram positive) 
  
Bacillus lintus (Gram negative) 
 
Escherichia coli (Gram negative) 
 
Fig: 33 
 
 
  
 
  
Pseudomonas aeruginosa (Gram negative) 
  
Rhodosporium rubrum (Gram negative) 
      
Vibrio cholera (Gram negative) 
Fig: 34 
 
 
  
ANTIFUNGAL ACTIVITY 
  
Candida albicans 
 
Aspergillus niger 
 
Aspergillus fumigates 
 
Aspergillus parasiticus  
Fig: 35 
 
  
3.10. IN-VITRO ANTIOXIDANT18 
 The 1, 1-diphenyl-2-picrylhydrazyl (DPPH) radical scavenging assay was first described 
by Blois in 1958 and was later modified slightly by numerous researchers. DPPH is a 
stable free radical that reacts with compound that can donate a hydrogen atom. This 
method is based on the scavenging of DPPH through the addition of a radical species or 
an antioxidant that change the color of DPPH solution from purple to yellow as the 
radical is quenched by the antioxidant. 
Reagents used 
Radical           : DPPH 
Solvent           : DMSO 
Standard         : Ascorbic acid 
Sample            : compounds BC 11a-BC 11e and BC 12a-BC 12e. 
Preparation of 0.3 mM DPPH solution 
It was prepared by dissolving DPPH (5.91 mg) in 50 ml of ethanol. This solution was 
prepared freshly and kept in the dark at an ambient temperature when not used. 
Preparation of sample stock solution 
The sample stock solution was prepared by dissolving the compound in suitable solvent 
(DMSO) with a final concentration of 1mg\ml. 
Preparation of standard stock solution 
The standard stock solution was prepared by dissolving the Ascorbic acid in suitable 
solvent (ethanol) with a final concentration of 1mg\ml. 
 
 
 
  
3.10.1. PROCEDURE 
 The effect of compound on DPPH radical was assayed by using the DPPH assay method. 
Sample stock solution (1mg\ml) was diluted to appropriate final concentration in DMSO. 
An ethanolic solution of 1ml of DPPH (0.3 mM) was added to 0.5 ml of compound and 
allowed to react at room temperature in a dark place for 30 minutes. After 30 minutes the 
absorbance values were measured at 518 ηm. All the measurements were taken as a 
triplicate values. From the average of the absorbance values, lower absorbance of the 
reaction mixture indicates higher free radical scavenging activity. The DPPH radical 
scavenging capability was calculated using the following equation. 
 
% inhibition = (ABS control – ABS test) \ ABS control × 100 
Where, ABS control = Absorbance of ethanol + DPPH 
ABS test = Absorbance of DPPH + Compound\Standard 
 
The percentage antioxidant activity (% inhibition) was extrapolated against concentration 
of the compound and EC50 was calculated by using graphical method. 
 
 
 
 
 
 
 
 
 
 
  
3.10.2. RESULT 
Antioxidant study was performed by DPPH assay method using the compounds (BC11a- 
BC11e & BC12a-BC12e).  
              
Fig: 36 % inhibition of compound BC11a                       Fig: 37 % inhibition of compound BC11b 
                   
    Fig: 38 % inhibition of compound BC11c                          Fig: 39 % inhibition of compound BC11d  
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    Fig: 40 % inhibition of compound BC11e                            Fig: 41 % inhibition of compound BC12a         
                     
Fig: 42 % inhibition of compound BC12b                              Fig: 43 % inhibition of compound BC12c         
                    
    Fig: 44 % inhibition of compound BC12d                          Fig: 45 % inhibition of compound BC12e 
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               Table 10: EC50 value of the synthesized compounds  
                                                                                                                                                                S.N Compounds
 
                           % Inhibition EC
50 
(µg) 
25µl 50 µl 75 µl 100 µl 
1 BC 11a 29.53   55.20 56.73 68.25 66 
2 BC 11b 55.87   58.81 63.72 64.48 - 
3 BC 11c 37.98 46.11 56.18 63.11 - 
4 BC 11d 57.06   68.16 78.24 90.97 18 
5 BC 11e 60.28   61.43 73.22 88.16 32 
6 BC 12a 35.91   53.05 57.28 60.04 - 
7 BC 12b 56.26   69.19 73.49 82.31 20 
8 BC 12c 60.64   65.98 68.16 83.03 60 
9 BC 12d  63.72   69.43   78.24   95.39 10 
10 BC 12e 63.56   70.25 83.79 91.32 11 
11 Ascorbic acid 68.48 77.35 89.71 96.46 22 
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Results & Discussion    
  
RESULTS AND DISCUSSION 
Chemistry and Synthesis 
2-aminobenzothiazole-6-carboxylic acid (BC 1) was prepared from p -aminobenzoic acid based 
on previously reported procedures. Basic hydrolysis of BC 1 was done followed by 
neutralization with hydrochloric acid and anhydrous Zinc chloride to yield Zinc salt of 4-amino-
3-mercaptobenzoic acid (BC 2). 
The synthesis of ester derivatives of 2-{4-[N’-(2-carboxyethyl) carbamimidamido] phenyl}-1, 3-
benzothiazole-6-carboxylic acid (BC 11a – BC 11e) are described in Series I.  As shown in 
Series I, compound BC 2 have been coupled immediately with p-nitrobenzoyl chloride to yield 
2-(4-nitro-phenyl) Benzothiazole-6-carboxylic acid (BC 3). Then the later was converted into 
acyl chloride (BC 5) followed by reduction with tin chloride to yield 2-(4-amino-phenyl)-
benzothiazole-6-carbonyl chloride (BC 7), which was coupled with ammoniumthiocyanate to 
yield 2-[4-(carbamothioylamino) phenyl]-1, 3-benzothiazole-6-carboxylic acid (BC 9), which 
was further coupled with β-alanine and triethylamine in tetrahydrofuran to yield 2-{4-[N’-(2-
carboxyethyl) carbamimidamido] phenyl}-1, 3-benzothiazole-6-carboxylic acid (BC 11). 
Esterification of BC 11 with alcohol derivatives with Con.sulphuric acid to yield the ester 
derivatives (BC 11a – BC 11e). 
The synthesis of ester derivatives of 2-{4-[N’-(2-carboxyethyl) carbamimidamido] methyl}-1, 3-
benzothiazole-6-carboxylic acid (BC 12a – BC 12e) are described in Series II.  As shown in 
Series II, compound BC 2 have been coupled immediately with bromoacetylbromide to yield 2-
(bromo methyl) Benzothiazole-6-carboxylic acid (BC 4). Then the later was converted into acyl 
chloride (BC 6) followed by ammonolysis  with ammonia to yield 2-(4-amino-methyl)-
benzothiazole-6-carbonyl chloride (BC 8), which was coupled with ammoniumthiocyanate to 
yield 2-[4-(carbamothioylamino) methyl]-1, 3-benzothiazole-6-carboxylic acid (BC 10), which 
was further coupled with β-alanine and triethylamine in tetrahydrofuran to yield 2-{4-[N’-(2-
carboxyethyl) carbamimidamido] methyl}-1, 3-benzothiazole-6-carboxylic acid (BC 12). 
Esterification of BC 12 with alcohol derivatives with Con.sulphuric acid to yield the ester 
derivatives (BC 12a – BC 12e). 
 
  
Physical properties 
Melting point 
Melting points were carried in open capillaries on Thomas However melting point apparatus 
which are uncorrected. A synthesized compounds melting point and its reactant melting points 
were recorded. A reactants and products melting point were differing from each others. It is 
clearly indicates that the formation of a new chemical entities. Melting points were given in 
table-1. 
Solubility 
Solubility properties of synthesized compounds were determined in various solvents and it was 
found that all compounds were completely soluble in DMSO, partially soluble in ethanol, 
chloroform and insoluble in water.  
Percentage of yield 
Percentage of yield of all synthesized compounds was calculated and values are given in the 
table-1. 
C Log P 
C Log P was calculated for all newly synthesized compounds using Chemsketch free version 
software and values are presented in the table-1. 
Thin layer chromatography 
Thin layer chromatography was performed for all newly synthesized compound as well as the 
parent compounds, all synthesized compounds gave a single spot whose Rf values are different 
from their reactants. It ultimately shows that completion of reaction and purity. The Rf values are 
summarized in table-2. 
 
 
 
  
IR-Spectroscopy 
Infra red spectroscopy was taken for all newly synthesized compounds. The characteristic peaks 
were observed for all the relevant groups.  
The absorption peaks around 1635.07cm-1 & 670.14cm-1 indicates that the formation of C=N & 
C-S stretching of Benzothiazole. The C=N peak was disappeared in step II.  Peaks around 1523-
1550cm-1& 650-700cm-1 were appeared for aromatic nitro compounds & aliphatic bromo 
compounds. This was disappeared in step 5 by the formation of amine, absorbs at 3200-3400cm-
1. Carboxylic acid strongly absorbs at 2500-3500cm-1 which was disappeared in step 4. Due to 
the formation of acid chloride absorbs at 1800cm-1(C=O) &850.02 (C-Cl). Peaks around 2070-
2085cm-1 was appeared for R-N=C=S stretch. Peaks around 1630-1650cm-1 (C=N), 2900-2800 
cm-1(CH2) & 2500-3500cm-1(COOH) indicates the formation of Guanidinopropionic acid in step 
6. The COOH peak was vanished in step 7 by the formation ester strongly absorbs at 1725-
1750cm-1. 
1HNMR Spectroscopy 
1H nuclear magnetic spectra were taken for selected synthesized compounds. An aromatic proton 
of Benzothiazole was appeared in all the synthesized compounds around 8.39-7.14 δppm (m, 
5H). Similarly phenyl & tolyl aromatic proton was observed in the region of 7.04- 6.95 δppm. 
Guanidine NH proton was seen at 4.34-3.6 δppm (s, 1H). A proton of methenyl group was 
appeared in 2.6-2.0 δppm (t, 2H).  
Mass Spectroscopy 
The mass spectral analysis of the selected synthesized compound BC 11d & BC 12e was 
performed and their mass spectrum of the compound was in agreement with its molecular 
weight. Molecular ion, [M+2] and base peaks are given in table-4. 
The characteristic [M+2] Cl isotope peak was also appeared in the spectrum.  
 
 
  
Biological activity  
In-vitro Aldose reductase inhibitory activity 
The synthesized compounds were screened for their inhibitory activity against Aldose reductase. 
Compounds BC 12d > BC 12e > BC 11d > BC 11e have showed inhibition 80%, 68%, 59% & 
53% respectively. Among these four, compound BC 12d was the most promising candidate and 
other compounds showed poor activity. The results are summarized in table-5. 
The results indicated that alkyl substituted Benzothiazole compound (BC 12d & BC 12e) showed 
good inhibitory activity than aryl substituted Benzothiazole compound (BC 11d & BC 11e). On 
the other hand aromatic ester derivatives of Benzothiazole (BC 12d, BC 12e, BC 11d & BC 11e)  
improves inhibition in comparison to aliphatic ester derivatives (BC 11a, BC 11b, BC 11c, BC 
12a, BC 12b & BC 12c). 
Docking studies with Aldose reductase 
In order to gain an insight into the binding mode of active compound BC 12d has been docked 
into the ligand binding pocket of Aldose reductase (PDB entry 2BGQ). Fig1 shows the 
corresponding interaction with ligand and protein. Results indicate hydrogen bond interactions 
(2.25 Å) between the carbonyl group of ester in compound and the catalytic amino acid residues 
Arg 265 and Ser 261.  
In-vitro Antioxidant activity 
Synthesized compounds were evaluated for antioxidant activity by DPPH method. Results are 
depicted in table-10. 
In both the series compounds BC 11d, BC 11e, BC 12d & BC 12e have identified promising 
antioxidant activity; it could be presence of phenyl & o- tolyl substituent at 3rd position of 
Guanidinopropionate. The antioxidant results depicted that the electron donating methylene 
linker derivatives have better activities than its counterpart. 
 
 
  
In-vitro Antimicrobial  
The synthesized compounds were screened for in vitro antibacterial and antifungal activity by 
Disc Diffusion and Serial Dilution technique using ciprofloxacin and clotrimazole drugs as 
reference standard.  Results were presented in (table 7-9). 
Antibacterial activity 
Compound BC 11d, BC 11e, BC 12d & BC 12e MIC (12.5 µg\ml) gave the moderate activity 
against Micrococcus lutes. 
Compounds BC 11d, BC 11e, BC 12d & BC 12e (MIC 12.5 µg\ml) showed moderate activity 
against Bacillus linctus. 
Compounds BC 11c, BC 11d, BC 11e, BC 12d & BC 12e (MIC 12.5 µg\ml) posses moderate 
activity against Staphylococcus aureus. 
Compounds BC 11b, BC 11c, BC 11d, BC 11e, BC 12d & BC 12e (MIC 12.5 µg\ml) thesaurus 
moderate activity against Bacillus substilis. 
Compounds BC 11c, BC 11d, BC 11e, BC 12d & BC 12e (MIC 12.5µg\ml) displayed moderate 
activity against Salmonella paratyphi. 
Compounds BC 11d, BC 11e, BC 12d & BC 12e (MIC 12.5µg\ml) showed moderate activity 
against Pseudomonas aeuroginosa. 
Compounds BC 11d, BC 11e, BC 12d & BC 12e (MIC 12.5µg\ml) displayed moderate activity 
against Vibrio cholera. 
Compounds BC 12d & BC 12e (MIC 6.25µg\ml) expressed moderate activity against E.coli. 
When compared to all the compounds, BC 11d, BC 11e BC 12d & BC 12e  possess antibacterial 
activity against all the tested bacteria but less potent than the Standard.  This activity might be 
due to the presence of phenyl & o-tolyl substituent at 3rd position of guanidinopropionate. 
 
 
  
Antifungal activity 
Compound BC 11e (MIC 6.25µg\ml) revealed moderate activity than the other compounds 
against Candida albicans. 
Compounds BC 11e & BC 12d (MIC 6.25µg\ml) exhibited moderate activity than the other 
compounds against Aspergillus niger. 
Compounds BC 11e, BC 12d & BC 12e (MIC 12.5µg\ml) have been showed moderate activity 
than the other compounds against Aspergillus fumigates.  
Compound BC 12d & BC 12e (MIC 6.25µg\ml) displayed moderate activity than the other 
compounds against Aspergillus parasites.   
When compared to all the compounds, BC 11e & BC 12d compound possess antifungal activity 
against all the tested fungi but not superior than the standard. This activity might be due to the 
presence of o phenyl & o-tolyl substituent at 3rd position of guanidinopropionate. 
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Conclusion 
 
 
  
CONCLUSION 
A new series of Benzothiazole fused Guanidinopropionic ester derivatives have been synthesized 
and evaluated for their potency as Aldose reductase inhibitors. Of those, compound BC 12d 
depicted as a potent compound with promising activity.  Additionally, it exhibited a high 
antioxidant potential to inhibit the formation of advanced glycation end products. Docking 
results suggested that compound BC 12d form hydrogen-bond interactions (2.25 Å) with the 
catalytic amino acid residues Arg 265 and Ser 261 of Aldose reductase. 
 
Further studies on its possible mechanism and in-vivo trials in experimental animals to broaden 
their pharmacological assessment.    
 
 
 
 
 
 
 
 
 
 
 
 
 
  
ABSTRACT 
A novel series of Benzothiazole fused Guanidinopropionic ester derivatives have been 
synthesized and characterized by FTIR, 1HNMR and mass spectral analysis. All the compounds 
were evaluated for their Aldose reductase (enzyme inhibition assay) and DPPH free radical 
(Scavenging assay) further more evaluated for antimicrobial activities (Disc diffusion and MIC 
method) against some pathogenic bacteria and fungi. Results revealed that, compound BC 12d 
exhibited promising AR inhibitory (80% inhibition, 10µm), free radical scavenging (95% 
inhibition) and antimicrobial activities (MIC 12.5-6.25µg\ml) at varied concentrations. The most 
active compound BC 12d has been docked into the crystal structure of Aldose reductase. 
Docking results indicate hydrogen bond interactions (2.25 Å) between the carbonyl group of 
ester in compound and the catalytic amino acid residues Arg 265 and Ser 261. 
 
